Crescita Therapeutics Stock Return On Equity
| CRRTF Stock | USD 0.45 0.00 0.00% |
Crescita Therapeutics fundamentals help investors to digest information that contributes to Crescita Therapeutics' financial success or failures. It also enables traders to predict the movement of Crescita Pink Sheet. The fundamental analysis module provides a way to measure Crescita Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Crescita Therapeutics pink sheet.
Crescita |
Crescita Therapeutics Company Return On Equity Analysis
Crescita Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Crescita Therapeutics Return On Equity | 0.0318 |
Most of Crescita Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Crescita Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Crescita Therapeutics has a Return On Equity of 0.0318. This is 100.13% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is 110.26% lower than that of the firm.
Crescita Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Crescita Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Crescita Therapeutics could also be used in its relative valuation, which is a method of valuing Crescita Therapeutics by comparing valuation metrics of similar companies.Crescita Therapeutics is currently under evaluation in return on equity category among its peers.
Crescita Fundamentals
| Return On Equity | 0.0318 | |||
| Return On Asset | 0.0227 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 3.64 M | |||
| Shares Outstanding | 20.4 M | |||
| Shares Owned By Insiders | 7.30 % | |||
| Price To Earning | 490.00 X | |||
| Price To Book | 0.66 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 16.77 M | |||
| Gross Profit | 10.01 M | |||
| EBITDA | 606 K | |||
| Net Income | (1.1 M) | |||
| Cash And Equivalents | 10.5 M | |||
| Cash Per Share | 0.51 X | |||
| Total Debt | 1.71 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 3.10 X | |||
| Book Value Per Share | 0.97 X | |||
| Cash Flow From Operations | (1.6 M) | |||
| Earnings Per Share | 0.02 X | |||
| Beta | 2.08 | |||
| Market Capitalization | 11.42 M | |||
| Total Asset | 28.92 M | |||
| Z Score | 3.6 | |||
| Net Asset | 28.92 M |
About Crescita Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Crescita Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crescita Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crescita Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Crescita Pink Sheet
Crescita Therapeutics financial ratios help investors to determine whether Crescita Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.